About Cure Pharmaceutical
Cure Pharmaceutical is a publicly listed company based in Oxnard (United States) founded in 2010. Oral thin film-based drug delivery systems are developed. Cure Pharmaceutical has raised $9.65 million across 10 funding rounds from investors including Gene Salkind. The company has 28 employees. Cure Pharmaceutical has completed 2 acquisitions, including Chemistry Holdings and Sera Labs. Cure Pharmaceutical offers products and services including CUREFilm®. Its focus areas include Life Sciences, Drug Delivery and Oral. Its competitors include Lyndra, i2o Therapeutics and Biora Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Cure Pharmaceutical was founded in 2010 in Oxnard, United States, focusing on pharmaceutical drug delivery innovations. Various platforms are developed, including oral thin films, liquid-based encapsulation, transdermal systems using epidermis penetration enhancers, and gastrointestinal delivery methods. Services provided encompass process development, manufacturing, and packaging design to support these technologies. Operations emphasize improved bioavailability compared to traditional forms like tablets and capsules.
- Headquarters Oxnard, United States
- Employees 28
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website curepharmaceutical.com
- Social LinkedIn X Facebook
- Legal Name Cure Pharmaceutical
- Total Equity Funding$9.65M (USD)
in 10 rounds
- Latest Funding Round$11.5M (USD), Post-IPO
Nov 2020
- Employee Count28
- Investments & AcquisitionsChemistry Holdings
& 1 more
Products & Services of Cure Pharmaceutical
Cure Pharmaceutical offers a comprehensive portfolio of products and services, including CUREFilm®.
Patented form for rapid sublingual absorption to improve medication efficacy.
Funding Insights of Cure Pharmaceutical
Cure Pharmaceutical has successfully raised a total of $9.65M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $11.5 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.65M
- Total Rounds 10
- Last Round Post-IPO — $11.5M
- First Round $2M
(Jul 2011)
- Investors Count 1
All 10 funding rounds of Cure Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $11.5M | Post-IPO | – | – | – |
| Feb 2018 | $1M | Post-IPO | – | – | |
| Oct 2016 | $80,000 | Series A | – | – | – |
| Oct 2016 | $250,000 | Series A | – | – | – |
| Dec 2015 | $323,212 | Series A | – | – | – |
| Nov 2015 | $6.03M | Series A | – | – | – |
| Mar 2013 | $300,000 | Debt – Conventional | – | – | – |
| Jul 2012 | $958,568 | Seed | – | – | – |
| Jul 2012 | Debt – Conventional | – | – | – | |
| Jul 2011 | $2M | Seed | – | – | – |
1 investors in total: 0 institutional and 1 angel.
Investors in Cure Pharmaceutical
Cure Pharmaceutical has secured backing from 1 investor, including angel investors. Prominent investors backing the company include Gene Salkind.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
GS Gene Salkind | unknown_9d69270624244317a |
Investor details for Cure Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cure Pharmaceutical
Cure Pharmaceutical has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Chemistry Holdings and Sera Labs.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of health and wellness products suing cannabis | seralabshealth.com | Lewiston, United States | 2018 | Jul 2020 | $20M | |
Limited information available | chemistryholdings.com | Santa Monica, United States | 2016 | Apr 2019 | •••• |
Complete acquisition details for Cure Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cure Pharmaceutical
6 dated milestones of Cure Pharmaceutical across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Cure Pharmaceutical is founded.
- Funding First funding round of $2.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Chemistry Holdings.
- Acquisition Acquires Sera Labs.
- Funding Latest funding round, Post-IPO, of $11.5M.
Competitors of Cure Pharmaceutical
Cure Pharmaceutical has 3 listed competitors in our database, 3 of them funded. They include Lyndra, i2o Therapeutics and Biora Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lyndra.com | 2015 | Cambridge, United States | $305.01M | 107 | Innovates long-acting oral therapies to simplify patient medication regimens. | |
| i2obio.com | 2019 | Boston, United States | $53.5M | 6 | Oral drug delivery solutions are provided via liquid technology platform. | |
| bioratherapeutics.com | 2010 | San Diego, United States | $116.62M | 54 | Smart pills are developed for targeted gastrointestinal drug delivery. |
Detailed competitors of Cure Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cure Pharmaceutical
The website of Cure Pharmaceutical (curepharmaceutical.com) receives about 2K visits a month and ranks #9,219,605 among all websites worldwide, #7,615 in Biotechnology and Pharmaceuticals.
- Monthly visits2K
▲ 29.9% vs previous month
- Global rank#9,219,605
among all websites
- Category rank#7,615
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit2.2
- Average visit1 min 09 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Cure Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocentury.com | 100% | 85.7K | #514,907 | View details | |
 mymanuel.wordpress.com | mymanuel.wordpress.com | 60% | – | ||
blogdefarmacia.com | blogdefarmacia.com | 60% | – |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Cure Pharmaceutical (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cure Pharmaceutical
Complete news archive for Cure Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cure Pharmaceutical
Cure Pharmaceutical was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Cure Pharmaceutical is headquartered in Oxnard, United States. It is registered at Oxnard, California, United States.
Cure Pharmaceutical is a funded company, having raised a total of $9.65M across 10 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Jul 2011.
Cure Pharmaceutical has 28 employees.
Cure Pharmaceutical was founded in 2010 in Oxnard, United States, focusing on pharmaceutical drug delivery innovations. Various platforms are developed, including oral thin films, liquid-based encapsulation, transdermal systems using epidermis penetration enhancers, and gastrointestinal delivery methods. Services provided encompass process development, manufacturing, and packaging design to support these technologies. Operations emphasize improved bioavailability compared to traditional forms like tablets and capsules.
Cure Pharmaceutical's top competitors include i2o Therapeutics, Biora Therapeutics and Lyndra.
Cure Pharmaceutical offers CUREFilm®.
Cure Pharmaceutical has made 2 acquisitions, including Chemistry Holdings, and Sera Labs.
Cure Pharmaceutical has 1 investor. Key investors include Gene Salkind.
Cure Pharmaceutical operates through Cure Pharmaceutical.